NCT06502691 - [18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2029

Conditions

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma

Interventions

OTHER

Best Practice

Receive of standard care

PROCEDURE

Biopsy of Breast

Undergo breast biopsy

PROCEDURE

Computed Tomography

Undergo FDG PET/CT

OTHER

Electronic Health Record Review

Ancillary studies

OTHER

Fludeoxyglucose F-18

Given FDG

RADIATION

Fluorine F 18 Fluorthanatrace

Given IV

DRUG

Immune Checkpoint Inhibitor

Receive ICI treatment

DRUG

Poly (ADP-Ribose) Polymerase Inhibitor

Receive PARP inhibitor treatment

PROCEDURE

Positron Emission Tomography

Undergo \[18F\]FTT PET

PROCEDURE

Positron Emission Tomography

Undergo FDG PET/CT

Trial Locations (1)

Fred Hutch/University of Washington Cancer Consortium, Seattle